Compare Five9 Inc (FIVN) vs Heron Therapeutics Inc (HRTX) Price & Performance

FIVN trades at $31.37, down 9.02% in the past day but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million. Recent management appointments and AI-driven subscription growth provide operational tailwinds.

Outlook is positive given earnings beats and analyst consensus, but risks include high valuation multiples and negative cash flow trends. The stock offers growth potential but requires monitoring of debt levels and competitive pressures in the CX software space.

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.